Enzyme therapy for the lysosomal storage disorders: principles,patents, practice and prospects

AstraZeneca progressed the long acting β₂ agonist into Phase II studies for the treatment of asthma and chronic obstructive pulmonary disease in August 2008. These three applications claim specific salt forms of three different long acting β₂ agonists, all benzothiazolone derivatives. It would seem that one claims AZD-3199 whereas the other two claim backup compounds.